IN THE LAB

In the lab

Our team is focused on expanding the applications and continuing the research and development of Nanovega technology. The unique capabilities of Nano-Antibodies bring great hope to cancer research, diagnostics, and eventually therapeutics with a technology that is safer, more effective, and less costly than current antibody-based technologies. We are committed to bringing this exciting tool to the scientists and healthcare professionals who make a difference in our lives.


Support

  • American Human Genetics Society
  • American Protein Society
  • American Antibody Society
  • American Medical Association
  • American Society for Clinical Chemistry
  • Wisconsin Alumni Research Foundation
  • Wisconsin Medical Foundation
  • American Society for Clinical Oncology

Marek Malecki MD PhD

President
Telephone: 415-640-9300
Fax: 415-640-9303
Email: marekmaleckimdphd@nanovega.com
Skype: President_Nanovega

Dr. Marek Malecki is the Founder, Chairman and President of Nanovega, Inc.

Dr. Malecki is currently the Principal Investigator of a project for the National Institutes of Health entitled “Engineering of Antibodies” and a Visiting Professor at the University of Wisconsin. He is the former Project Coordinator for the National Institutes of Health National Biotechnology Resource and former Director of the Molecular Imaging Laboratories at the University of California, San Diego.

Dr. Malecki is also currently the Editor in Chief for several peer-reviewed scientific journals including the Journal of Genetic Syndromes & Gene Therapy, the Journal of Stem Cell Research & Therapy and the Journal of Regenerative Medicine. He is also an Editorial Board Member for the peer-reviewed scientific journals Frontiers: Genetics, Journal of Molecular and Cell Therapy – Regenerative Medicine and the Journal of Cancer Research and Therapy. Dr. Malecki has also authored numerous peer-reviewed scientific publications which have been published in a number of highly regarded scientific journals.

Dr. Malecki is currently the inventor of Nano-Antibodies which are protected by six patent applications pending at the USPTO and WIPO. He is also the member of a number of Professional Societies including the AMA, ASHG, APS, SCBC and Rho Phi Society for Excellence in Teaching and Faculty Role Models. NORBB patents.justia.com/inventor/marek-malecki www.google.com/?q=Malecki+Marek www.ncbi.nlm.nih.gov/pubmed/?term=Malecki+M www.google.com/?q=Malecki+Marek cellgenetherapy2014.conferenceseries.net/speaker community.frontiersin.org/people/MarekMalecki www.selectbiosciences.com/conferences/biographies www.f1000.com/prime www.google.com/search?q=Marek+Malecki

Randy Berholtz JD

Chief Executive Officer
Telephone: 858-205-5091
Fax: 858-205-5092
Email: CEO@nanovega.com
Skype: CEO_Nanovega

Randy Berholtz is the Chief Executive Officer and a member of the Board of Directors of Nanovega, Inc.

He is a longtime executive and attorney for companies in the life science, venture capital and legal industries.He has held executive positions with Apricus Biosciences, Inc., a public pharmaceutical company (Nasdaq), the ACON Group, a group of private Chinese and US life science companies, IngleWood Ventures, L.P., a San Diego-based life sciences venture fund and Nanogen, Inc., a public genomics tools company (Nasdaq).

He currently serves on the Board of Directors of Strategic Drug Solutions, Inc., a biopharmaceutical company, is a consultant to Innovus Pharmaceuticals, Inc., a pharmaceutical company and is on the Advisory Council of the Keck Graduate Institute of Applied Sciences at the Claremont Colleges (“KGI”). He was previously on the board of directors of four other life science companies.

He is also an Adjunct Professor of Law at the Thomas Jefferson School of Law and has also taught biotechnology law, patent law, patent litigation and business law at the University of San Diego School of Law, the Rady School of Business at the university of California, San Diego and at KGI. He has also worked for the law firms of Heller Ehrman, LLP, Cooley Godward, LLP, Kirkpatrick & Lockhart, LLP (now K&L Gates) and Cravath, Swaine & Moore, LLP.He is a graduate of Cornell University, Oxford University where he was a Rhodes Scholar and the Yale Law School. http://www.ventanavc.com/002A.CMS?Managing-Director http://www.tjsl.edu/directory/randy-berholtz http://www.linkedin.com/pub/randy-berholtz/3/659/165 http://www.youtube.com/watch?v=vDFmo5omGLo
For pricing information contact us:
415-640-9300
info@nanovega.com
Title
fluorescent at 619nm
BT HTFR F619
superparamagnetic at 0.4 - 11T
BT HTFR SPM
x-ray opaque at 10 - 150keV
BT HTFR XR
Title
HTFR fluorescent at 619nm
BT HTFR F619
HEGFR fluorescent at 619nm
BT HEGFR1 F619
HEGFR2 fluorescent at 619nm
BT HEGFR1 F619
HEGFRvIII fluorescent
BT HEGFRvIII

Synthetic Nano-Antibodies (snAbs)

Synthetic Nano-Antibodies (snAbs) are biomolecules designed in silico and manufactured in vitro with no involvement of animals. They have the three-dimensional structure corresponding to the variable fragments of antibodies – the targeting domains of all kinds of antibodies.  Initial constructs were patterned based upon modeling of the human IgG molecules synthesized in vitro by human B cells. To date, the snAbs were manufactured against cancers of breast, ovary, testis, prostate, but the works on other cancers continue.


BioTags

The snAbs are incorporated as parts of more complex molecules – BioTags. In there, they serve as the targeting domains guiding BioTags to selected cells. The BioTags are designed in silico and manufactured in vitro. In addition to the targeting domains, they have incorporated other domains allowing them to fulfill other functions:  internalizations into the cells, entering selected cell organelles (e.g., mitochondria to reach mitochondrial DNA or nuclei to reach specific genes); escaping some cellular organelles to avoid destruction (e.g., lysosomes). Therefore, they are de facto non-viral vectors.


Protection of Intellectual Property

All the elements of biomolecular engineering are protected by the patent applications at the USPTO and WIPO. They also cover all aspects of streamlining into the clinics.


External validation of biotechnology

The DNA, mRNA, and AA sequences are accessible through NCBI, USPTO, and WIPO publications. They are free for academic works, but the IP is protected for commercial purposes.


Verification of the results by publications in peer-reviewed journals

All the data from the laboratory studies, as well as the results of the small scale clinical trials were published in the peer-reviewed journals and indexed in PubMed.

Highlighting cancer tissue during oncological surgery

The very main problem for surgeons pursuing debulking surgery of a cancerous tumor is to remove its maximal volume, while leaving most of healthy tissues undisturbed. This is very difficult task, as in the operating field it is often very difficult to distinguish cancerous tumor from healthy tissue. The snAbs and BioTags offer a way to solve this problem. As we demonstrated, the fluorescent snAbs label the cancer cells with high efficacy. They highlight only the tumor cells during the surgery. Therefore, they can guide the surgeons in tractu of the operation. As such, the snAbs open the routes for laser-guided and laser-performed surgery.


Isolating spectra of single cancer cells for next generation sequencing of their genomes

The two main problems for systemic chemical therapy of cancer are: therapeutic resistance and adverse effects. The cancers are heterogenous, i.e., hey consist of different populations of cells, which are refractive or responding to therapy. To date, determination of the therapeutic efficacy is practically ex iuvantibus. Whole genome next generation sequencing can resolve this problem if it is conducted not on homogenates of all cells, but on single cells representing specific populations of cells within the tumor. Systemic chemo-therapeutics target the cancer and healthy cells alike. The assumption is that cancer cells are little more sensitive than healthy cells. Nevertheless, pursuing chemotherapy is equivalent to walking a very thin line between killing the cancer and hurting the patient. Targeted therapeutics are aimed to change this paradigm by delivering the therapeutic drug or genes to the cancer cells only,but not to the healthy cells. The snAbs are the primary tool for the avant-garde of physicians and scientists pioneering personalized medicine. With the very high specificity and sensitivity, they facilitate isolating single cells and NGS of their genomes.


Molecular imaging of cancer in vivo

BioTags are engineered on such a way that they specialized domains hosting various reporting atoms. Therefore, they are compatible with all modern imaging equipment and medical infrastructure including but not limited to X-Ray, MRI, CAT and PET.


Protection of Intellectual Property

All the elements of biomolecular engineering are protected by the patent applications at the USPTO and WIPO. They also cover all aspects of streamlining into the clinics.


External validation of biotechnology

The DNA, mRNA, and AA sequences are accessible through NCBI, USPTO, and WIPO publications. They are free for academic works, but the IP is protected for commercial purposes.


Verification of the results by publications in peer-reviewed journals

All the data from the laboratory studies, as well as the results of the small scale clinical trials were published in the peer-reviewed journals and indexed in PubMed.